Human liver single nuclear RNA sequencing implicates BMPR2, GDF15, arginine, and estrogen in portopulmonary hypertension
Name:
s42003-023-05193-3.pdf
Size:
3.289Mb
Format:
PDF
Description:
Final Published Version
Author
Jose, A.Elwing, J.M.
Kawut, S.M.
Pauciulo, M.W.
Sherman, K.E.
Nichols, W.C.
Fallon, M.B.
McCormack, F.X.
Affiliation
Department of Medicine, University of Arizona-PhoenixIssue Date
2023-08-09
Metadata
Show full item recordPublisher
Nature ResearchCitation
Jose, A., Elwing, J.M., Kawut, S.M. et al. Human liver single nuclear RNA sequencing implicates BMPR2, GDF15, arginine, and estrogen in portopulmonary hypertension. Commun Biol 6, 826 (2023). https://doi.org/10.1038/s42003-023-05193-3Journal
Communications BiologyRights
© The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Portopulmonary hypertension (PoPH) is a type of pulmonary vascular disease due to portal hypertension that exhibits high morbidity and mortality. The mechanisms driving disease are unknown, and transcriptional characteristics unique to the PoPH liver remain unexplored. Here, we apply single nuclear RNA sequencing to compare cirrhotic livers from patients with and without PoPH. We identify characteristics unique to PoPH in cells surrounding the central hepatic vein, including increased growth differentiation factor signaling, enrichment of the arginine biosynthesis pathway, and differential expression of the bone morphogenic protein type II receptor and estrogen receptor type I genes. These results provide insight into the transcriptomic characteristics of the PoPH liver and mechanisms by which PoPH cellular dysfunction might contribute to pulmonary vascular remodeling. © 2023, Springer Nature Limited.Note
Open access journalISSN
2399-3642PubMed ID
37558836Version
Final Published Versionae974a485f413a2113503eed53cd6c53
10.1038/s42003-023-05193-3
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License.
Related articles
- Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2).
- Authors: Al-Naamani N, Krowka MJ, Forde KA, Krok KL, Feng R, Heresi GA, Dweik RA, Bartolome S, Bull TM, Roberts KE, Austin ED, Hemnes AR, Patel MJ, Oh JK, Lin G, Doyle MF, Denver N, Andrew R, MacLean MR, Fallon MB, Kawut SM, , for the Pulmonary Vascular Complications of Liver Disease Study Group
- Issue date: 2021 Feb
- Comparison of Post-Liver Transplantation Outcomes in Portopulmonary Hypertension and Pulmonary Venous Hypertension: A Single-Center Experience.
- Authors: Rajaram P, Parekh A, Fisher M, Kempker J, Subramanian R
- Issue date: 2017 Mar
- Portopulmonary Hypertension: Management and Liver Transplantation Evaluation.
- Authors: DuBrock HM
- Issue date: 2023 Jul
- Portopulmonary hypertension.
- Authors: Lv Y, Han G, Fan D
- Issue date: 2016 Jul
- Evolving dilemmas and management of portopulmonary hypertension.
- Authors: Krowka MJ
- Issue date: 2006 Aug